Consonance Capital Management LP Adma Biologics, Inc. Transaction History

Consonance Capital Management LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$1.67 - $2.95 $2.6 Million - $4.6 Million	-1,558,290 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.04 - $3.74 $2.24 Million - $4.11 Million	-1,100,000 Reduced 41.38%	1,558,290 $3.72 Million
Q2 2020 Aug 14, 2020	SELL	$2.42 - $3.29 $1.75 Million - $2.39 Million	-725,000 Reduced 21.43%	2,658,290 $7.79 Million
Q1 2020 May 15, 2020	SELL	$1.5 - $4.59 $2.68 Million - $8.19 Million	-1,783,671 Reduced 34.52%	3,383,290 $9.74 Million
Q4 2019 Feb 14, 2020	BUY	$3.89 - $5.15 $202,182 - $267,671	51,975 Added 1.02%	5,166,961 $20.7 Million
Q3 2019 Nov 14, 2019	SELL	$3.19 - $5.39 $1.88 Million - $3.18 Million	-590,366 Reduced 10.35%	5,114,986 $22.8 Million
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $3.93 Million - $5.85 Million	1,117,000 Added 24.34%	5,705,352 $22.1 Million
Q4 2018 Feb 14, 2019	BUY	$2.17 - $6.12 $106,453 - $300,228	49,057 Added 1.08%	4,588,352 $11 Million
Q3 2018 Nov 14, 2018	BUY	$4.39 - $6.85 $1.27 Million - $1.99 Million	290,061 Added 6.83%	4,539,295 $28.2 Million
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $4.04 Million - $5 Million	920,000 Added 27.63%	4,249,234 $19.2 Million
Q1 2018 May 15, 2018	SELL	$3.21 - $5.21 $123,267 - $200,069	-38,401 Reduced 1.14%	3,329,234 $15.3 Million
Q4 2017 Feb 14, 2018	BUY	$2.06 - $3.24 $4.31 Million - $6.78 Million	2,093,702 Added 164.35%	3,367,635 $10.8 Million
Q3 2017 Nov 14, 2017	BUY	$2.76 - $3.71 $3.52 Million - $4.73 Million	1,273,933	1,273,933 $3.92 Million

319

184M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.48B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.